Abstract
Pseudophakic cystoid macular edema (PCME) remains the most common cause of poor visual outcome following cataract surgery. Whereas acute PCME may resolve itself spontaneously, some patients will suffer from vision impairment and will be difficult to treat. Although PCME has already been described approximately 50 years ago, its pathophysiology remains uncertain and a multitude of mechanisms have been suggested. As broad as the mechanisms, as many are the treatment options. Topical nonsteroidal anti-inflammatory agents (NSAIDs) and corticosteroids either as mono- or combined therapy are a commonly used first line approach. When ineffective, systemic treatment with these agents may be an option. Alternatively, intravitreal application of corticosteroids and anti-vascular endothelial growth factor (anti-VEGF) may offer an effective option, if first-line treatment fails. A critical evaluation of the current literature revealed that the optimal treatment of PCME remains unclear and requires further investigation. In addition, prevention should be of foremost importance and remains an open issue. Identification of risk factors, application of NSAIDs and consequent follow-up are potential essential steps in the avoidance of this complication.
Keywords: Cataract surgery, corticosteroids, nonsteroidal anti-inflammatory agents, pseudophakic cystoid macular edema.
Current Pharmaceutical Design
Title:Controversies in NSAIDs Use in Cataract Surgery
Volume: 21 Issue: 32
Author(s): Mikaella-Anthia Tsangaridou, Andrzej Grzybowski, Enken Gundlach and Uwe Pleyer
Affiliation:
Keywords: Cataract surgery, corticosteroids, nonsteroidal anti-inflammatory agents, pseudophakic cystoid macular edema.
Abstract: Pseudophakic cystoid macular edema (PCME) remains the most common cause of poor visual outcome following cataract surgery. Whereas acute PCME may resolve itself spontaneously, some patients will suffer from vision impairment and will be difficult to treat. Although PCME has already been described approximately 50 years ago, its pathophysiology remains uncertain and a multitude of mechanisms have been suggested. As broad as the mechanisms, as many are the treatment options. Topical nonsteroidal anti-inflammatory agents (NSAIDs) and corticosteroids either as mono- or combined therapy are a commonly used first line approach. When ineffective, systemic treatment with these agents may be an option. Alternatively, intravitreal application of corticosteroids and anti-vascular endothelial growth factor (anti-VEGF) may offer an effective option, if first-line treatment fails. A critical evaluation of the current literature revealed that the optimal treatment of PCME remains unclear and requires further investigation. In addition, prevention should be of foremost importance and remains an open issue. Identification of risk factors, application of NSAIDs and consequent follow-up are potential essential steps in the avoidance of this complication.
Export Options
About this article
Cite this article as:
Tsangaridou Mikaella-Anthia, Grzybowski Andrzej, Gundlach Enken and Pleyer Uwe, Controversies in NSAIDs Use in Cataract Surgery, Current Pharmaceutical Design 2015; 21(32) . https://dx.doi.org/10.2174/1381612821666150909101804
DOI https://dx.doi.org/10.2174/1381612821666150909101804 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Role of microRNAs in Vascular Remodeling
Current Molecular Medicine Nocturnal Blood Pressure Abnormalities in Obstructive Sleep Apnea - Clinical Predictors
Current Respiratory Medicine Reviews Cellular Membrane Microparticles: Potential Targets of Combinational Therapy for Vascular Disease
Current Vascular Pharmacology Editorial (Thematic Issue: Vascular Dysfunction in Obesity and Insulin Resistance)
Current Vascular Pharmacology Predementia and Dementia Syndromes: Possible Role of Lipoprotein Metabolism
Vascular Disease Prevention (Discontinued) Multi-target Activities of Selected Alkaloids and Terpenoids
Mini-Reviews in Organic Chemistry Correlations Between Carotid IMT, Factor VIII Activity Level and Metabolic Disturbances: A Cardio-Vascular Risk Factor in the HIV Positive Persons
Current HIV Research From Bitopic Inhibitors to Multitarget Drugs for the Future Treatment of Alzheimer’s Disease
Current Medicinal Chemistry Epigenetic and Disease Targets by Polyphenols
Current Pharmaceutical Design Low Estimated Glomerular Filtration Rate is Associated with High Recurrence Rate and Poor Prognosis of Hemorrhage Stroke
Current Neurovascular Research Cardio-Vascular Risks Associated with Clozapine Treatment
Current Psychiatry Reviews Development of Nitric Oxide Donors for the Treatment of Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Blood Pressure and Vascular Alterations with Growth in Childhood
Current Pharmaceutical Design BHUx: A Patented Polyherbal Formulation to Prevent Hyperlipidemia and Atherosclerosis
Recent Patents on Inflammation & Allergy Drug Discovery Vascular Disease: A New Progenitor Biology
Current Vascular Pharmacology Subject Index to Volume 2
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Long-Term Outcome of Cardio Respiratory Exercise Performance After Surgery
Current Respiratory Medicine Reviews A Review of the Efficacy and Cardiovascular Safety of Amylin Analogues
Current Drug Safety Regulation of Endothelial Cell Death and Its Role in Angiogenesis and Vascular Regression
Current Neurovascular Research Meet Our Editorial Board Member
Letters in Drug Design & Discovery